Biomedical subjects

Yuji Nakamoto

Publications and source records attributed to Yuji Nakamoto.

At least 19 recordsLinked to original sources

PubMed2007

Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.

OBJECTIVE: The purpose of this study was to compare the diagnostic performance of manually fused PET images obtained using 18F-FDG and CT images with that of CT alone, PET alone, and conventional side-by-side review of PET images and CT images (hereafter referred to as "PET + CT") in patients with suspected recurrent colorectal cancer. MATERIALS AND METHODS: Ethics committee approval and informed consent were obtained. Sixty-three patients with suspected recurrent colorectal cancer underwent whole-body 18F-FDG PET followed by diagnostic CT. The acquired PET and CT images were merged on a workstation on a pixel-to-pixel basis. CT, PET, PET + CT, and fused images were evaluated separately in terms of the presence or absence of recurrence, new metastases, or both using a 5-point grading scale (0 = definitely negative, 1 = probably negative, 2 = equivocal, 3 = probably positive, and 4 = definitely positive). Lesions determined to be grade 3 or 4 were considered positive, and diagnostic accuracy and certainty were evaluated with statistical analysis using the chi-square test for independence. RESULTS: Of 119 pathologically or clinically confirmed lesions in 36 patients, evaluation of CT, PET, PET + CT, and fused images resulted in the detection of 75 (63%), 84 (71%), 91 (76%), and 111 (93%) lesions, respectively (p < 0.01) with the number of grade 4 lesions detected being 59 (50%), 72 (61%), 84 (71%), and 108 (91%), respectively (p < 0.01). Overall, the diagnostic accuracy of CT, PET, PET + CT, and fused images according to patient were 78%, 79%, 84%, and 92%, respectively (p = 0.13). CONCLUSION: Interpreting fused images provided more accurate diagnoses than interpreting CT, PET, or PET + CT images. This method of manually fusing separately obtained PET and CT images increased the diagnostic certainty for detecting colorectal cancer recurrence and decreased the number of equivocal cases.

Adult↗

PubMed2006

Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET.

UNLABELLED: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has become widely available and an important oncological technique. To evaluate the influence of PET on detection of bone metastasis, we compared the diagnostic accuracy of PET and conventional bone scintigraphy (BS) in a variety of cancer patients. METHODS: Consecutive ninety-five patients with various cancers, who received both PET and BS within one month, were retrospectively analyzed. A whole-body PET (from face to upper thigh) and a standard whole body BS were performed and these images were interpreted by two experienced nuclear medicine physicians with and without patient information using monitor diagnosis. Each image interpretation was performed according to 8 separate areas (skull, vertebra, upper limbs, sternum and clavicles, scapula, ribs, pelvis, and lower limbs) using a 5-point-scale (0: definitely negative, 1: probably negative, 2: equivocal, 3: probably positive, 4: definitely positive for bone metastasis). RESULTS: Twenty-one of 95 patients (22.1%) with 43 of 760 areas (5.7%) of bone metastases were finally confirmed. In untreated patients, 12 of 14 bone metastasis positive patients were detected by PET, while 9 of 14 were detected by BS. Three cases showed true positive in PET and false negative in BS due to osteolytic type bone metastases. In untreated cases, PET with and without clinical information showed better sensitivity than BS in patient-based diagnosis. For the purpose of treatment effect evaluation, PET showed better results because of its ability in the evaluation of rapid response of tumor cells to chemotherapy. Out of 10 cases of multiple-area metastases, 9 cases included vertebrae. There was only one solitary lesion located outside of FOV of PET scan in the femur, but with clinical information that was no problem for PET diagnosis. CONCLUSION: Diagnostic accuracy of bone metastasis was comparable in PET and BS in the present study. In a usual clinical condition, limited FOV (from face to upper thigh) of PET scan may not be a major drawback in the detection of bone metastases because of the relatively low risk of solitary bone metastasis in skull bone and lower limbs.

Adolescent↗

PubMed2006

Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard.

UNLABELLED: The SET-3000 G/X (clinical tomograph with high resolution and a large axial field of view) is a 3-dimensional (3D) (only) dedicated PET camera with germanium oxyorthosilicate (GSO) and bismuth germanate (BGO) scintillators. The main characteristic of the SET-3000 G/X PET scanner is 3D continuous-emission and spiral-transmission (CEST) scanning, yielding a reduction in whole-body scan time. We evaluated the physical performance of the SET-3000 G/X PET scanner with the National Electrical Manufacturers Association (NEMA) NU 2-2001 standard. METHODS: A GSO 3D emission scanner is combined with a BGO transmission scanner separated axially by a lead shield. In the GSO scanner, small and thick scintillators (2.45 x 5.1 x 30 mm(3)) are arranged in small blocks (23.1 x 52 mm) to achieve high resolution and a high counting rate. The detector ring has a large solid angle with a diameter of 664 mm and an axial coverage of 260 mm (50 rings). The transmission scanner consists of BGO block detectors with a diameter of 798 mm and an axial width of 23.1 mm and is equipped with a rotating (137)Cs point source of 740 MBq and a tungsten collimator. The low- and high-energy thresholds are set to 400 and 700 keV, respectively, in the emission system. The coincidence time window is set to 6 ns. In CEST acquisition, the patient couch moves continuously through the emission and transmission scanners in a 1-way motion. Emission coincidence data are acquired in the histogram mode with on-the-fly Fourier rebinning, and transmission single data are acquired with emission contamination correction. RESULTS: With the NEMA NU 2-2001 standard, the main performance results were as follows: the average (radial and tangential) transverse and axial spatial resolutions (full width at half maximum) at 1 cm and at 10 cm off axis were 3.49 and 5.04 mm and 4.48 and 5.40 mm, respectively; the average sensitivity for the 2 radial positions (0 and 10 cm) was 20.71 cps/kBq; the scatter fraction was 50%; the peak noise equivalent count rate was 62.3 kcps at 9.8 kBq/mL; and the peak random rate was 542.1 kcps at 37.6 kBq/mL. CONCLUSION: The new integrated SET-3000 G/X PET scanner has good overall performance, including high resolution and sensitivity, and has the potential of reducing whole-body acquisition time to less than 10 min while improving small-lesion detectability with a low radiation dose.

Equipment Design↗

PubMed2005

Normal FDG distribution patterns in the head and neck: PET/CT evaluation.

PURPOSE: To retrospectively evaluate the distribution of fluorine 18 fluorodeoxyglucose (FDG) in the head and neck region with combined positron emission tomography-computed tomography (PET/CT) in patients with no known abnormality in this region. MATERIALS AND METHODS: The institutional review board allowed a retrospective review of PET/CT images obtained in 78 patients with non-head and neck cancer and waived the requirement for informed consent. The accumulation of FDG in 11 normal head and neck structures was visually and quantitatively assessed retrospectively. Positive rate percentage (PRP) was defined as the sum of the percentages of patients with grade 2 and grade 3 tracer uptake intensity. Standardized uptake values (SUVs) were calculated for quantitative analysis. Mean SUVs were compared between the male and female patients by using the unpaired t test, and the correlation between FDG uptake and patient age was assessed by using the Pearson correlation coefficient test. RESULTS: Intense tracer uptake was usually seen in the palatine tonsils (PRP, 98%; mean SUV, 3.48), soft palate (PRP, 96%; mean SUV, 3.13), and lingual tonsils (PRP, 96%; mean SUV, 3.11). In the inferior concha (PRP, 4%; mean SUV, 1.56), thyroid gland (PRP, 3%; mean SUV, 1.31), and tongue (PRP, 1%; mean SUV, 1.39), uptake was typically minimal. FDG accumulation was variable in the sublingual glands (PRP, 72%; mean SUV, 2.93), spinal cord (PRP, 64%; mean SUV, 2.12), submandibular glands (PRP, 53%; mean SUV, 2.11), parotid glands (PRP, 51%; mean SUV, 1.90), and vocal cords (PRP, 19%; mean SUV, 1.77). The mean normal-tissue SUV in the soft palate was higher in male than in female patients (P <.01). A negative correlation between age and physiologic FDG uptake was seen in the palatine tonsils (r=-0.51, P <.001) and sublingual glands (r=-0.70, P <.001). CONCLUSION: Intense FDG uptake was usually observed in the palatine tonsils, lingual tonsils, and soft palate, whereas uptake in the major salivary glands was variable.

Adolescent↗

PubMed2005

CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination.

PURPOSE: To retrospectively evaluate lesion findings at computed tomography (CT) performed as part of a combined positron emission tomography (PET)/CT examination in patients suspected of having metastatic bone lesions-lesions that were detected with fluorine 18 fluorodeoxyglucose (FDG) PET as part of the same examination-and to correlate the CT and FDG PET findings. MATERIALS AND METHODS: This HIPAA-compliant study had institutional review board approval, and the need for patient informed consent was waived. Three hundred fifty-nine consecutive patients (191 male patients, 168 female patients; mean age, 56.9 years; age range, 8-92 years) underwent PET/CT. PET images were first reviewed by nuclear medicine physicians who had no clinical information regarding the presence or absence of bone metastasis by using a five-point grading system (0, a lesion was definitely negative for metastasis; 1, a lesion was probably negative; 2, a lesion was equivocal; 3, a lesion was probably positive; and 4, a lesion was definitely positive). For lesions assigned a grade of 3 or 4 at PET, CT characteristics such as the presence or absence of morphologic changes or accompanying findings (including bone destruction) were assessed by radiologists on the CT images obtained during the same imaging session. RESULTS: One hundred seventy-nine lesions in 55 patients were considered to be probable or definite bone metastases at PET. One hundred thirty-three of these lesions in 33 patients were clinically confirmed to be bone metastases at follow-up and/or histopathologic examination. CT revealed osteolytic changes in 41 (31%) and osteoblastic changes in 21 (16%) of the 133 lesions, but no or nonspecific changes were seen at CT in 49 (37%) and 22 lesions (17%), respectively. Of the 179 lesions suspected at PET, 46 ultimately proved to be nonosseous or false-positive for bone metastasis. Of these 46 lesions, 38 were not located in the bone but in adjacent tissues such as the pleura. CONCLUSION: CT images obtained as part of PET/CT scanning were useful in yielding the precise location of bone lesions and thus helping avoid misdiagnosis of bone metastasis; however, CT revealed morphologic changes in only half of the lesions assigned a grade of 3 or 4 at PET.

Adolescent↗

PubMed2005

Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.

PURPOSE: To retrospectively compare fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) and computed tomographic (CT) findings at the same anatomic locations in patients with lymphoma by using a combined PET/CT scanner and to analyze the lesions on metabolic and anatomic bases to evaluate causes of discrepant findings between the two modalities. MATERIALS AND METHODS: The institutional review board allowed an exempt retrospective review of cancer PET database, and informed consent was waived. The study was HIPAA compliant. Fifty-three patients with lymphoma (20 Hodgkin and 33 non-Hodgkin; mean age, 43 years; range, 12-83 years) who underwent FDG PET/CT were included. The PET and CT images were interpreted by two nuclear medicine physicians and one radiologist, respectively, blinded to the other imaging findings. Concordant PET and CT findings were regarded as positive or negative for lymphoma. The site with discordant findings was defined as positive for disease if it was accompanied by other PET- and CT-positive sites in the same patient or was confirmed clinically (histologic examination or progressive disease). Staging results were also compared by one nuclear medicine physician. RESULTS: Of a total of 1537 anatomic sites in 53 patients, 48 had discordant findings between PET and CT. Forty (83%) of the 48 sites had correct PET findings (31 positive, nine negative), five had correct CT findings, and three were unresolved. The 31 PET-positive and CT-negative sites accounted for 23% of all 134 true-positive PET sites. PET provided accurate staging in an incremental nine (17%, upstaging in four and downstaging in five) of 53 patients in whom CT staging was incorrect. CT provided correct upstaging in two patients. CONCLUSION: FDG PET/CT as a combined modality may contribute substantially to lesion characterization and staging in patients with lymphoma.

Adolescent↗

PubMed2005

[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

PURPOSE: The aim of this study was to evaluate the relationships among [18F]fluorodeoxyglucose ([18F]-FDG) uptake, Glut-1 and HK-II expressions, and grade of inflammation in resected lung lesions. MATERIALS AND METHODS: Sixty patients had undergone preoperative 18F-FDG-PET imaging and thoracotomy. For semiquantitative analysis of 18F-FDG uptake, partial volume effect corrected maximum standardized uptake values (pSUVs) were calculated. Immunohistochemical staining was performed in resected specimens using anti-Glut-1, anti-HK-II, and anti-proliferative cellular nuclear antigen (PCNA) antibodies, and immunoreactivities were scored as G-, H-, and P-indexes on a five-point scale (0: 0%; 1: 20%, 2: 40%; 3: 60%; 4: 80%, and 5: 100% percentages of strongly immunoreactive cells).Grade of inflammation was also evaluated. RESULTS: The malignant lesions had higher pSUV and higher G- and H- than nonmalignant lesions. pSUVs correlated with the G- (p < .001), H- (p < .01), and P-indexes (p < .01) in malignant lesions. In adenocarcinomas, cancers with lower differentiation showed higher expression of Glut-1 and HK-II than those with higher differentiation. A positive linear regression was observed between pSUVs and the grading of inflammation in nonmalignant lesions (p < .05). CONCLUSIONS: Our study indicates that 18F-FDG uptake in lung cancer correlates well with the Glut-1, HK-II, and PCNA expression. For nonmalignant lesions, the presence of a higher inflammatory process correlated with 18F-FDG uptake.

Adenocarcinoma↗

PubMed2005

Accuracy of image fusion using a fixation device for whole-body cancer imaging.

OBJECTIVE: The purpose of this study was to evaluate the clinical feasibility of a simple image fusion technique with PET and CT images acquired separately using a vacuum cushion as a fixation device. SUBJECTS AND METHODS: Forty-four patients underwent whole-body PET using 18F-fluoro-2-deoxy-D-glucose (FDG) followed by CT with IV contrast material. The patients were carefully fixed in an individually molded cushion to provide the same positioning for both examinations. The PET and CT images were fused on a workstation by using the lower margin of the urinary bladder as a reference. The degree of misregistration was evaluated for the physiologic uptake of the liver and kidneys and for the pathologic uptake of lesions. RESULTS: The average deviation of the center point of the liver between the two images was 6.6 +/- 8.7 (SD) mm in the craniocaudal direction, 1.9 +/- 5.1 mm in the anteroposterior direction, and 2.3 +/- 7.0 mm in the right-left direction. This value in the craniocaudal direction was 4.7 +/- 8.7 mm in the right kidney and 4.0 +/- 8.8 mm in the left kidney. Above the diaphragm, the deviations of the center point of movable and static lesions were 11.7 +/- 3.4 mm and 10.4 +/- 5.3 mm, respectively. Below the diaphragm, those of movable and static lesions were 9.7 +/- 2.5 mm and 6.9 +/- 2.9 mm, respectively. CONCLUSION: Our preliminary data indicate that this technique is a simple and practical method for manual image fusion that may be acceptable in clinical settings.

Feasibility Studies↗

PubMed2004

Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.

PURPOSE: Recently, dual-phase 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) was shown to be useful in the differentiation between malignant and benign pancreatic lesions. The aim of this prospective study was to evaluate the value of dual-phase FDG-PET as a prognostic parameter in patients with pancreatic cancer. METHODS: Sixty-five consecutive patients with pancreatic cancer underwent dual-phase FDG-PET. Standardised uptake values at 1 h (SUV1) and 2 h (SUV2) following the injection of FDG were determined, and the retention index (RI) was calculated by dividing the difference between SUV2 and SUV1 by SUV1. The prognostic value of SUV1, SUV2 and RI was analysed, along with the various clinical and biochemical parameters. RESULTS: Multivariate analysis showed that only three factors had an independent association with longer patient survival: female gender (p<0.01), TNM stage I-III (p<0.05) and RI>10% (p<0.01). Neither SUV1 nor SUV2 showed any prognostic significance. Combination of tumour stage and RI allowed more accurate prognostic evaluation. Patients at stage I-III with RI>10% survived longer than did patients at the same stage with RI<10% (15.3 vs 11.5 months, p<0.01). Patients at stage IV with RI>10% had an intermediate prognosis, with a median survival of 9.5 months; patients at stage IV with RI<10% showed the worst prognosis, with a median survival of 4.9 months (p<0.05). CONCLUSION: RI calculated with dual-phase FDG-PET can be used not only as a tool for initial diagnosis and staging of pancreatic cancer but also as a strong independent prognostic parameter that can allow accurate identification of those patients who will benefit from intensive anticancer treatment at different stages of the disease.

Female↗

PubMed2004

18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy.

This study was performed to investigate the feasibility of FDG- and L-[methyl-11C]methionine (Met)-PET for the follow up of lung cancer after stereotactic radiotherapy (SRT). Nine patients (pt) with solitary lung cancer underwent SRT. Met- and FDG-PET studies were performed one week before SRT and from one week to 8 months after SRT. Responses to SRT were complete in 2 pt and partial in 7 pt. Met- and FDG-PET scan showed high tracer uptake in all tumors before SRT. After SRT, standardized uptake values (SUV) of FDG and Met changed concordantly. Both decreased with time in 5 pt but did not decrease steadily in 4 pt, where 2 pt showed an increase at 1 to 2 weeks after SRT and 2 pt showed an increase at more than 3 months after SRT. The former appears to reflect the acute reaction to SRT and the latter radiation-induced pneumonitis. Although the addition of Met-PET did not provide additional information over FDG-PET, FDG- and Met-PET could be used to evaluate the treatment effect of SRT.

Aged↗

PubMed2004

Usefulness of FDG-PET in detecting an ADH-secreting tumor: a case report.

We report a case of a 41-year-old woman who was diagnosed as having the syndrome of inappropriate secretion of ADH (SIADH). There was no evidence of any disorders of the central nervous system, lung diseases, or drugs causing SIADH. Positron emission tomography (PET) using (18)F-fluorodeoxyglucose (FDG) was performed and indicated a tumor of the uterine cervix. After resection of the tumor, both serum sodium level and serum osmolarity were normalized concomitantly with a decrease in serum ADH level. This is the first case report suggesting the usefulness of a FDG-PET scan to detect an occult cancer responsible for SIADH. It seems plausible that FDG-PET may be helpful in the diagnosis of other ectopic hormone-producing tumors such as ectopic ACTH-producing tumors that cause Cushing's syndrome.

Journal Article↗

PubMed2004

PET/CT: artifacts caused by bowel motion.

BACKGROUND AND AIM: In a combined positron emission tomography (PET) and computed tomography (CT) system, the CT images can be used for attenuation correction as well as for image fusion. However, quantitative and qualitative differences have been reported between CT based attenuation corrected PET and conventional transmission scan corrected PET images. The purpose of this study was to investigate potential differences in PET/CT caused by attenuation differences in bowel due to motion. METHODS: Twelve patients had PET/CT scans performed using 68Ge transmission and CT attenuation correction methods. Three emission imaging datasets were generated including CT corrected PET, Ge corrected PET, and the difference images (CT corrected PET minus Ge corrected PET). PET difference images were used to identify regions of mismatch and to quantify possible discordance between images by using standardized uptake values (SUVs). Using the Ge corrected PET as the standard, differences in emission images were classified as an overestimation (pattern A) or an underestimation (pattern B) in these difference images. RESULTS: One hundred and twenty-three mismatched areas were identified. Among them, overestimated areas in CT corrected image were detected in 36 regions (pattern A), while underestimated areas were evaluated in the remaining 87 regions (pattern B). The mean value of the difference in pattern A (mean +/- standard deviation = 0.84 +/- 0.44) was slightly higher than that in pattern B (0.60 +/- 0.23), and statistically significant. Six of 36 regions in pattern A had an SUV of greater than 2.5 in CT corrected PET but less than 2.5 in Ge corrected PET; two of 87 regions with pattern B demonstrated an SUV greater than 2.5 in Ge corrected PET and less than 2.5 in CT corrected PET. CONCLUSION: Physiological bowel motion may result in attenuation differences and subsequent differences in SUVs. Overestimation of fluorodeoxyglucose uptake should not be misinterpreted as disease.

Abdominal Neoplasms↗

PubMed2004

[Evaluation of optimized injection dose and acquisition time using body mass index for three-dimensional whole-body FDG-PET].

OBJECTIVE: The standardized uptake value (SUV) is a relative measure of tracer uptake in tissue used in (18)F-FDG PET. However, the quality of ordered subset expectation maximization (OS-EM) images is sensitive to the number of iterations, because a large number of iterations leads to images with checkerboard noise. The main advantage of data acquisition in the three-dimensional (3D) mode is the high sensitivity to better exploit the intrinsic spatial resolution and the lower injection dose given to patients. In the 3D mode, the scatter fraction is higher, and, for a given administered dose, the random fraction is higher than that in the two-dimensional mode, which implies that correction methods need to be more accurate. Moreover, in clinical oncology (18)F-FDG PET studies, patients have a wide variety of body shapes and sizes, which may impact image statistics. Consequently, it is necessary to make constant the acquisition (true) counts. The purpose of this study was to optimize injection dose and acquisition time in consideration of body mass index (BMI) for 3D whole-body (18)F-FDG PET. METHODS: A dedicated PET scanner, SIEMENS ECAT EXACT HR(+), was used to scan images of clinical data. The injection dose for BMI of <14-19, 19-22, 22-25, and 25< (kg/m(2)) were, 92.5 MBq, 111.0 MBq, 129.5 MBq, and 148.0 MBq, respectively. The emission scan time per bed position for BMI of <14-19, 19-22, 22-25, and >25 (kg/m(2)) were, 120, 120, 180, and 240 sec, respectively. A total of 20 patient subjects were evaluated as to true counts per bin (T/bin) of sinogram data and measured activity concentrations for the region of interest in the liver section. RESULTS: T/bin was stable using an optimized protocol that took into consideration the BMI for any type of body morphology. The overall coefficient of variation was 7.27% for radioactivity concentration. Additionally, Gaussian filtering (8 mm FWHM) after reconstruction by the OS-EM method provided stable SUV values even when the iteration number was increased 30 times over. CONCLUSION: Optimization of injection dose and acquisition time indicated that BMI was a clinically useful acquisition protocol for 3D whole-body (18)F-FDG PET.

Body Mass Index↗

PubMed2003

Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.

UNLABELLED: The usefulness of fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) in differentiated thyroid cancer (DTC) has been demonstrated by many investigators, but in only a small number of studies have FDG-PET images been compared with those obtained using other non-iodine tumour-seeking radiopharmaceuticals. In most of the studies, planar imaging was performed for comparison using thallium-201 chloride or technetium-99m 2-methoxyisobutylisonitrile ((99m)Tc-MIBI). Furthermore, FDG-PET studies were not always performed in the hypothyroid state with increased levels of thyroid stimulating hormone (TSH), which are known to increase FDG uptake by DTC. The aim of this study was to compare the ability of FDG-PET to detect metastatic DTC with that of (99m)Tc-MIBI whole-body single-photon emission tomography (SPET) and post-therapeutic iodine-131 scintigraphy, evaluated under TSH stimulation. Nineteen patients (8 men, 11 women; age range, 38-72 years, mean 60 years; 17 thyroidectomised and 2 inoperable patients following (131)I ablation of the remaining thyroid tissue; 16 papillary and 3 follicular carcinomas) with metastatic DTC underwent FDG-PET whole-body scan (WBS) and (99m)Tc-MIBI SPET WBS at an interval of less than 1 week, followed by (131)I therapy. The SPET images were reconstructed using the maximum likelihood expectation maximisation (ML-EM) method. All patients were hypothyroid at the time of each scan. (131)I WBS was performed 3-5 days after oral administration of the therapeutic dose. A total of 32 lesions [10 lymph node (LN), 15 lung, 6 bone, 1 muscle] were diagnosed as metastases, as confirmed by histopathology and/or other imaging modalities (X-ray, US, CT, MRI, bone, (201)Tl and (131)I scans). FDG-PET, (99m)Tc-MIBI SPET and post-therapeutic (131)I scintigraphy respectively revealed a total of 26 (81.3%), 20 (62.5%) and 22 (68.8%) lesions. These techniques respectively demonstrated nine (90.0%), eight (80.0%) and six (60.0%) LN metastases, and eleven (73.3%), seven (46.7%) and ten (66.7%) lung metastases. They each demonstrated five of the six bone metastases (83.3%). FDG-PET and (99m)Tc-MIBI SPET were positive in 17 (78.3%) and 14 (63.6%) of the 22 (131)I-positive lesions, respectively, and also in nine (90.0%) and six (60.0%) of the ten (131)I-negative lesions, respectively. Three of the five (131)I-positive and FDG-PET-negative lesions were miliary type lung metastases with a maximal nodular diameter of less than 10 mm. Comparison of FDG-PET with (99m)Tc-MIBI SPET revealed concordant results in 24 lesions, and discordant results in eight lesions (seven with positive FDG-PET alone and one with positive (99m)Tc-MIBI SPET alone). IN CONCLUSION: (a) even using whole-body SPET, FDG PET is superior to (99m)Tc-MIBI in terms of ability to detect metastases of DTC; (b) the higher sensitivity of FDG-PET compared with the previous studies could partly be due to increased serum TSH.

Adenocarcinoma, Follicular↗

PubMed2003

Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis.

PURPOSE: To evaluate fluorine 18 fluorodeoxyglucose (FDG) uptake in the thoracic aortic wall at combined positron emission tomography (PET)/computed tomography (CT) and compare uptake with aortic wall calcification. MATERIALS AND METHODS: Records of 85 consecutive cancer patients who underwent FDG PET/CT were evaluated retrospectively. One hour after FDG injection, CT followed by PET was performed from ear to middle of the thigh. CT, PET, and fused PET/CT images were generated. FDG uptake and calcification were evaluated visually and semiquantitatively. FDG uptake was graded according to intensity; calcification, according to thickness. Unpaired t test was used for comparison of patient age with and without FDG uptake and with and without calcification. The relationship between the score (sum of grades along all aortic segments) of positive FDG uptake and calcification and patient age was analyzed with Spearman rank correlation. Comparison of frequency of FDG uptake and calcification with age, sex, risk factors for cardiovascular disease (CVD), or history of CVD was performed with chi2 analysis. RESULTS: Fifty patients had at least one area of FDG uptake in thoracic aortic wall, 14 of whom showed focal FDG uptake. Intermediate to intense FDG uptake tended to be observed in the descending aorta. Forty-five patients had at least one measurable aortic calcification. Thick calcification was observed most often at the aortic arch. Twelve patients had 13 uptake areas at the calcification site. Patients with positive findings were on average older (P <.05 for both increased uptake and calcification); the older patient group had higher frequency of both aortic wall uptake (P <.005) and calcification (P <.001). The calcification score correlated with age (rho = 0.60, P <.001) but the FDG uptake score did not. Women, patients with hyperlipidemia, and patients with history of CVD tended to show increased FDG uptake (P =.073,.080, and.068, respectively), whereas patients with diabetes had significantly more calcifications (P <.05). CONCLUSION: PET/CT depicted FDG uptake commonly in the thoracic aortic wall. The FDG uptake site was mostly distinct from the calcification site and may possibly be located in areas of metabolic activity of atherosclerotic changes.

Adolescent↗

PubMed2003

Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.

The feasibility of small animal imaging using a clinical positron emission tomography/computed tomography (PET/CT) scanner with [F-18]-fluoro-2-deoxy-D-glucose (FDG) was evaluated. As tumor-bearing small animal models, rabbits with VX-2 liver tumors, rats with mammary tumors on the back, and mice with LS174T human colon tumor xenografts were prepared. Two-dimensional PET, CT, and fused PET/CT images were obtained and reconstructed with a combined PET/CT system using a conventional protocol for humans and dedicated high-resolution mode protocols specialized for each species. Estimated radioactivity concentrations in tumors and normal organs determined noninvasively on FDG-PET/CT were compared with the actual tissue radioactivity levels determined from gamma-counting after vivisection in rats. In addition, recovery-corrected radioactivity concentrations were calculated and evaluated using the tumor/normal organ sizes measured on CT. Tumors in rabbits and rats were clearly visualized by FDG-PET/CT in the dedicated protocols, and images were considered suitable for research purposes. With the aid of thin-slice CT-mapping images, FDG uptake was correctly localized in the viable tumor regions. In mice, increased FDG uptake in tumors with varying activity levels was observed, but detailed anatomical information was not optimally provided from the images, even using specialized protocols. The estimated radioactivity concentrations of tumors and normal organs were close to the actual radioactivity concentrations obtained by gamma-counting (r = 0.97, P < 0.001, the estimated/actual slope: 1) when recovery correction was applied using the sample sizes measured on CT. FDG-PET/CT imaging with a modern clinical scanner was demonstrated to be feasible, of excellent quality, and quite quantitatively accurate for research in rabbits or rats with tumors of appropriate size (>2 cm without recovery correction and >1 cm with recovery correction). Evaluation of FDG uptake within a tumor was possible with the aid of CT images. Dedicated small animal PET/CT scanner would be better suited for evaluating tumor-bearing mice and likely could enhance imaging smaller tumors in rabbits or rats. Although it has limitations, small animal imaging with a clinical PET/CT scanner may be quite adequate for sequential noninvasive imaging in oncology research because the CT is of high resolution, allowing for localization of PET findings and for more precise noninvasive estimation of radioactivity concentration through partial volume corrections.

Animals↗

PubMed2003

Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT.

Although PET/CT scanners have the potential for precise fused registration of structures visualized on both PET and CT, physiological motion during the acquisition of both studies may alter the appearance of organ shape, size or location. The degree of possible mismatch in abdominal organ size and position between PET and CT has not been evaluated. The aim of this study was to assess the consistency in location and measured size of upper abdominal organs with PET and CT using a combined PET/CT system. Forty-six consecutive inpatients who underwent clinical PET/CT scans for suspected cancer were evaluated. CT and PET images attenuation corrected by both CT and germanium-68 transmission scans were obtained, and we separately determined the location of the top and bottom (height), anterior and posterior margins (thickness), and right and left margins (width) for each organ, including liver, spleen, and bilateral kidneys, using CT and both sets of PET images. Differences between the two modalities in terms of location and measured organ size were investigated. In the upper margin of the liver and lower margin of the spleen, more than 10% of the cases showed a larger discrepancy (>20 mm) between CT-based and Ge-corrected PET-based measurements, although the differences in the positions of the edges were less than 10 mm in most cases. The center of the liver tended to be located cephalad and to the right of the body, and that of the spleen tended to be cephalad and posterior on PET, as compared with CT. Moreover, the center of both kidneys tended to be seen cephalad, posterior, and to the right on PET. The liver appeared slightly larger on PET than CT in thickness (CT vs CT-corrected PET vs Ge-corrected PET = 156 mm vs 162 mm vs 162 mm) and width (186 mm vs 189 mm vs 188 mm). By contrast, the spleen appeared slightly smaller on PET than CT in height (84 mm vs 77 mm vs 80 mm) and width (85 mm vs 81 mm vs 80 mm). A similar tendency was observed in the left kidney (105 mm vs 100 mm vs 99 mm in height, and 64 mm vs 59 mm vs 58 mm in width) and the right kidney (99 mm vs 93 mm vs 93 mm in height, and 64 mm vs 59 mm vs 60 mm in width). These differences between the two modalities were statistically significant ( P<0.05). In conclusion, minor mismatches in location and organ size were found to exist between CT and PET images, in part due to physiological motion. Although these differences could potentially affect the quality of the image registrations, they were generally of a modest nature.

Abdomen↗

PubMed2003

Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT.

PET-CT scanners allow generation of transmission maps from CT. The use of CT attenuation correction (CTAC) instead of germanium-68 attenuation correction (Ge AC) might be expected to cause artifacts on reconstructed emission images if differences in respiratory status exist between the two methods of attenuation correction. The aim of this study was to evaluate for possible respiratory motion artifacts (RMA) in PET images attenuation corrected with CT from PET-CT in clinical patients. PET-CT scans were performed using a Discovery LS PET-CT system in 50 consecutive patients (23 males, 27 females; mean age 58.2 years) with known or suspected malignancy. Both CTAC and Ge AC transmission data obtained during free tidal breathing were used to correct PET emission images. Cold artifacts at the interface of the lungs and diaphragm, believed to be due to respiratory motion (RMA), that were seen on CTAC images but not on the Ge AC images were evaluated qualitatively on a four-point scale (0, no artifact; 1, mild artifact; 2, moderate artifact; 3, severe artifact). RMA was also measured for height. Curvilinear cold artifacts paralleling the dome of the diaphragm at the lung/diaphragm interface were noted on 84% of PET-CT image acquisitions and were not seen on the (68)Ge-corrected images; however, these artifacts were infrequently severe. In conclusion, RMA of varying magnitude were noted in most of our patients as a curvilinear cold area at the lung/diaphragm interface, but were not diagnostically problematic in these patients.

Abdominal Neoplasms↗